Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer

Journal of Endocrinological Investigation

Volumn 32, Issue 5, 2009, Pages 426-429

  Raitila, A ^a   Georgitsi, M ^a   Bonora, E ^b   Vargiolu, M ^b   Tuppurainen, K ^c   Makinen M J ^c   Vierimaa, O ^c   Salmela, P I ^c   Launonen, V ^a   Vahteristo, P ^a   Aaltonen, L A ^a   Romeo, G ^b   Karhu, A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

AIP; Familial NMTC; Germline mutation; Thyroid cancer

Indexed keywords

AROMATIC HYDROCARBON; ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; RECEPTOR INTERACTING PROTEIN; UNCLASSIFIED DRUG;

AIP GENE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILIAL DISEASE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MORTALITY; PROTEIN ANALYSIS; THYROID CANCER; THYROID FOLLICLE CELL;

EID: 70350344060     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346480     Document Type: Article

References (43)

1. Roman SA. Endocrine tumors: Evaluation of the thyroid nodule. Curr Opin Oncol 2003, 15: 66-70.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998, 83: 2638-2648
3. Faquin WC. The thyroid gland: Recurring problems in histologic and cytologic evaluation. Arch Pathol Lab Med 2008, 132: 622-632
4. Lesueur F, Stark M, Tocco T, et al. Genetic heterogeneity in familial nonmedullary thyroid carcinoma: Exclusion of linkage to RET, MNG1, and TCO in 56 families. NMTC consortium. J Clin Endocrinol Metab 1999, 84: 2157-2162 (Pubitemid 30647048)
5. Loh KC. Familial nonmedullary thyroid carcinoma: A meta-review of case series. Thyroid 1997, 7: 107-113 (Pubitemid 27132904)
6. Grossman RF, Tu SH, Duh QY, Siperstein AE, Novosolov F, Clark OH. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg 1995, 130: 892-899
7. Bignell GR, Canzian F, Shayeghi M, et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997, 61: 1123-1130 (Pubitemid 27492321)
8. Canzian F, Arnati P, Harach HR, et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998, 63: 1743-1748 (Pubitemid 30415737)
9. Malchoff CD, Sarfarazi M, Tendler B, et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: Genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000, 85: 1758-1764 (Pubitemid 32269272)
10. McKay JD, Lesueur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001, 69: 440-446 (Pubitemid 32695216)
11. Cavaco BM, Batista PF, Sobrinho LG, Leite V. Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density SNP genome-wide linkage analysis. J Clin Endocrinol Metab 2008, 93: 4426-4430 (Pubitemid 352789543)
12. Malchoff CD, Malchoff DM. Familial nonmedullary thyroid carcinoma. Cancer Control 2006, 13: 106-110
13. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the carney complex: Diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001, 86: 4041-4046
14. Beckers A, Daly AF. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. Eur J Endocrinol 2007, 157: 371-382 (Pubitemid 350018439)
15. Vierimaa O, Georgitsi M, Lehtonen R, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312: 1228-1230 (Pubitemid 43801151)
16. Daly AF, Vanbellinghen JF, Khoo SK, et al. Aryl hydrocarbon receptor interacting protein gene mutations in familial isolated pituitary adenomas: Analysis in 73 families. J Clin Endocrinol Metab 2007, 92: 1891-1896
17. Cazabat L, Libe R, Perlemoine K, et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: Mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 2007, 157: 1-8. (Pubitemid 47162559)
18. McKay JD, Thompson D, Lesueur F, et al. Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer. J Med Genet 2004, 41: 407-412 (Pubitemid 38788034)
19. Kauppinen-Makelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90: 4081-4086 (Pubitemid 41058176)
20. Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol 1991, 220: 49-65. (Pubitemid 121004542)
21. Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, Brunak S. Splice site prediction in arabidopsis thaliana pre-mRNA by combining local and global sequence information. Nucleic Acids Res 1996, 24: 3439-3452 (Pubitemid 26294458)
22. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in genie. J Comput Biol 1997, 4: 311-323
23. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003, 31: 3568-3571 (Pubitemid 37442199)
24. Tchourbanov A, Ali HH. Combinatorial method of splice sites prediction, 2005. IEEE Computational Systems Bioinformatics Conference (CSB'05) 2005, 189-190
25. Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 2006, 15: 2490-2508 (Pubitemid 44288702)
26. Wang M, Marin A. Characterization and prediction of alternative splice sites. Gene 2006, 366: 219-227 (Pubitemid 43230165)
27. Georgitsi M, Raitila A, Karhu A, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor- interacting protein gene mutations. Proc Natl Acad Sci USA 2007, 104: 4101-4105 (Pubitemid 47181585)
28. Georgitsi M, Karhu A, Winqvist R, et al. Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer 2007, 96: 352-356 (Pubitemid 46160642)
29. Buchbinder S, Bierhaus A, Zorn M, Nawroth PP, Humpert P, Schilling T. Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non- secreting pituitary adenomas. Exp Clin Endocrinol Diabetes 2008, 116: 325-328
30. Herrmann BL, Baumann H, Janssen OE, Gorges R, Schmid KW, Mann K. Impact of disease activity on thyroid diseases in patients with acromegaly: Basal evaluation and follow-up. Exp Clin Endocrinol Diabetes 2004, 112: 225-230 (Pubitemid 38679265)
31. Siegel G, Tomer Y. Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature. Endocr Res 2005, 31: 51-58 (Pubitemid 41419984)
32. Tita P, Ambrosio MR, Scollo C, et al. High prevalence of differentiated thyroid carcinoma in acromegaly. Clin Endocrinol (Oxf) 2005, 63: 161-167 (Pubitemid 41097984)
33. Kurimoto M, Fukuda I, Hizuka N, Takano K. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute. Endocr J 2008, 55: 67-71.
34. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol 2003, 12: 69-90. (Pubitemid 37289013)
35. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148: 948-953
36. Barlier A, Vanbellinghen JF, Daly AF, et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab 2007, 92: 1952-1955 (Pubitemid 46997216)
37. Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol (Oxf) 2007, 66: 499-502. (Pubitemid 46434927)
38. Naves LA, Daly AF, Vanbellinghen JF, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol 2007, 157: 383-391
39. Raitila A, Georgitsi M, Karhu A, et al. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia. Endocr Relat Cancer 2007, 14: 901-906 (Pubitemid 350074077)
40. Toledo RA, Lourenco DM Jr, Liberman B, et al. Germline mutation in the aryl hydrocarbon receptor interacting protein (AIP) gene in familial somatotropinoma. J Clin Endocrinol Metab 2007, 92: 1934-1937.
41. Georgitsi M, Heliovaara E, Paschke R, et al. Large genomic deletions of aryl hydrocarbon receptor interacting protein (AIP) gene in pituitary adenoma predisposition. J Clin Endocrinol Metab 2008, 93: 4146-4151
42. Georgitsi M, De Menis E, Cannavo S, et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf) 2008, 69: 621-627
43. Leontiou CA, Gueorguiev M, van der Spuy J, et al. The role of the AIP gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 2008, 93: 2390-2401